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The Role of CD4 T Cells in the Pathogenesis of Murine AIDS
Wen Li1 and William R. Green1,2*
Department of Microbiology and Immunology, Dartmouth Medical School,1 and Norris Cotton Cancer Center,
Dartmouth Hitchcock Medical Center,2 Lebanon, New Hampshire 03756
Received 25 December 2005/Accepted 3 March 2006
LP-BM5, a retroviral isolate, induces a disease featuring retrovirus-induced immunodeficiency, designated
murine AIDS (MAIDS). Many of the features of the LP-BM5-induced syndrome are shared with human
immunodeficiency virus-induced disease. For example, CD4 T cells are critical to the development of MAIDS.
In vivo depletion of CD4 T cells before LP-BM5 infection rendered genetically susceptible B6 mice MAIDS
resistant. Similarly, MAIDS did not develop in B6.nude mice. However, if reconstituted with CD4 T cells,
B6.nude mice develop full-blown MAIDS. Our laboratory has shown that the interaction of B and CD4 T cells
that is central to MAIDS pathogenesis requires ligation of CD154 on CD4 T cells with CD40 on B cells.
However, it is not clear which additional characteristics of the phenotypically and functionally heterogeneous
CD4 T-cell compartment are required. Here, in vivo adoptive transfer experiments using B6.nude recipients
are employed to compare the pathogenic abilities of CD4 T-cell subsets defined on the basis of cell surface
phenotypic or functional differences. Th1 and Th2 CD4 T cells equally supported MAIDS induction. The rare
Thy1.2 CD4 subset that expands upon LP-BM5 infection was not necessary for MAIDS. Interestingly,
CD45RBlow CD4 T cells supported significantly less disease than CD45RBhigh CD4 T cells. Because the
decreased MAIDS pathogenesis could not be attributed to inhibition by CD45RBlow CD25 natural T-
regulatory cells, an intrinsic property of the CD45RBlow cells appeared responsible. Similarly, there was no
evidence that natural T-regulatory cells played a role in LP-BM5-induced pathogenesis in the context of the
intact CD4 T-cell population.
The LP-BM5 retroviral isolate consists of a pathogenic de-
fective murine leukemia virus (BM5def) that requires the rep-
lication-competent ecotropic helper virus BM5eco for its entry
into cells and spread in vivo. The ensuing AIDS variety, termed
murine AIDS (MAIDS) (25), exhibits many features shared
with human immunodeficiency virus (HIV)-induced disease in
humans (3, 7, 55). These similar features include early-onset
hypergammaglobulinemia (hyper-Ig), splenomegaly, and lymph-
adenopathy; dependence on CD4 T cells for initiation of disease;
loss of CD4 T-cell function; severely depressed T- and B-cell
responses; increased susceptibility to infection and death when
exposed to normally nonpathogenic microorganisms; and the de-
velopment of terminal B-cell lymphomas. These MAIDS-associ-
ated “opportunistic” lymphomas occur under these immunodefi-
ciency conditions in susceptible C57BL/6 mice and are generally
similar to the lymphoid tumors observed in human AIDS pa-
tients.
Interaction between B and CD4 T cells is critical for the
pathogenesis of MAIDS: both CD4 T cells and B cells are
required for disease induction and progression. Severe com-
bined immunodeficient (SCID) mice (lacking mature T and B
cells) do not develop MAIDS (52). The main targets of LP-
BM5 retrovirus infection are B cells and, to some extent, mac-
rophages and T cells. However, B-cell infection is not progres-
sive and does not lead to disease in the absence of mature CD4
T cells (8, 23). Indeed, an early hyperactivity of CD4 T cells
may contribute to the pathogenesis of MAIDS (39, 60). In vivo
depletion of CD4 T cells before LP-BM5 infection rendered
susceptible B6 mice resistant to the development of MAIDS.
Similarly, congenitally athymic nude B6 mice are resistant to
LP-BM5-induced disease (39). However, if reconstituted with
CD4 T cells from B6 donor mice, B6.nude recipients develop
MAIDS upon LP-BM5 infection (15, 19, 60). In further adop-
tive transfer experiments it was found that B6.nude recipients,
if reconstituted with CD154/, but not CD154/, CD4 T
cells, were converted to disease susceptibility (19). With regard
to the cell type interacting with the CD154 CD4 T cells, B6
CD40/ mice, which are relatively resistant to LP-BM5-in-
duced MAIDS, became susceptible to LP-BM5-induced dis-
ease after reconstitution with highly purified wild-type B cells
but not after receiving purified wild-type dendritic cells or a
combined CD40 population composed of dendritic cells and
macrophages obtained from B6.SCID mouse donors (19). In a
recent follow-up study, we showed that the CD80/CD86 (B7.1/
B7.2) costimulatory ligands are not required for LP-BM5 in-
duction of MAIDS (17). These results and other data (36)
suggested that CD4 T-cell-expressed CD28 ligation is not re-
quired for the initiation of MAIDS or the early commitment
to disease progression. Although this classic upregulation of
CD80/CD86 after CD40 ligation is thus not necessary, we have
used a panel of CD40 Tg mice on the CD40/ background to
confirm that the CD40 signaling is required for MAIDS induc-
tion and is differentially mediated by TRAF binding to the
TRAF 6 site (versus the TRAF 2/3/5 site) on the CD40 cyto-
plasmic tail (16). Collectively, these findings provide clear
evidence that activated CD4 T-cell CD154 ligation of B-cell
CD40 and downstream signaling events are required for
MAIDS (16, 19).
Beyond this series of reports, however, surprisingly little is
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known about other CD4 T-cell features required for the in-
duction of MAIDS. Several studies have examined the effects
of established MAIDS disease on the CD4 T-cell compart-
ment, i.e., characterization of CD4 T-cell anergy (2, 21, 41, 59),
but there are few prospective studies defining the role of these
CD4 T-cell features in the induction of MAIDS. The molecu-
lar basis for the requirement for CD4 T cells for MAIDS
induction is thus incompletely understood. The relevant ques-
tion is as follows: which phenotypic and/or functional charac-
teristics of CD154 CD4 T cells are critical for mediating
MAIDS? To address the role of CD4 T cells in MAIDS in-
duction and pathogenesis, we performed a series of in vivo
adoptive transfer experiments designed to determine which
subpopulation(s) of CD154 CD4 T cells, as defined on the
basis of relevant cell surface phenotypic and functional differ-
ences, are essential for LP-BM5-induced MAIDS. This ap-
proach allows direct comparisons in a system where MAIDS
induction is dependent on the transferred cells.
MATERIALS AND METHODS
Mice. Male B6 mice were purchased from the National Institutes of Health
(Bethesda, MD), housed in the Dartmouth Medical School Animal Resource
Center, and used when they reached 8 to 10 weeks of age as control mice or
spleen cell donors. B6.nude breeder mice were purchased from The Jackson
Laboratory (Bar Harbor, ME) and were bred to increase group size at the
Dartmouth Medical School Animal Resource Center. Equal numbers of B6.nude
mice, either three or four in a given experimental group, were reconstituted with
various cell preparations (see below) before infection with LP-BM5 virus.
LP-BM5 virus inoculations. LP-BM5 virus was prepared in our laboratory as
previously described (22). Briefly, G6 cells cloned from SC-1 fibroblasts infected
with the LP-BM5 virus mixture and originally provided by Janet Hartley and
Herbert Morse (NIH/NIAID, Bethesda, MD) were cocultured with uninfected
SC-1 cells. Mice were infected intraperitoneally (i.p.) with 1 105 ecotropic PFU
virus stock.
Splenocyte subpopulation preparations. Splenocyte suspensions were labeled
with various antibody-coupled paramagnetic beads (MACS; Miltenyi Biotec,
Auburn, CA) and subjected to column purification according to the manufac-
turer’s protocol or sorted by use of a FACStar Plus instrument with TurboSort
(Becton Dickinson Immunocytometry Systems, Mountain View, CA). The puri-
fied cellular subsets indicated below were used in reconstitution experiments; in
each case, a portion of the recipients of such adoptive transfer was infected with
LP-BM5 48 h after adoptive transfer, and the remaining mice receiving adoptive
cell transfer served as uninfected controls.
(i) CD4 T-cell preparations. Spleen cell suspensions were labeled with anti-
CD4 beads, and positive selection yielded cell preparations which were 98%
CD4 and less than 1% B220 and CD8 together, as detected by flow cytometric
analysis. Alternatively, negative selection of CD4 T cells was accomplished
by using anti-CD8, -CD19, -CD11b, and -CD11c beads; for the collected
flowthrough, designated as CD4 negatively selected cells, the purity was 98%.
CD4 T cells (1  107 unless otherwise indicated) obtained by either positive or
negative selection were adoptively transferred intravenously into B6.nude recip-
ients.
(ii) Generation of CD4 Th1-like and Th2-like cell preparations in vitro. Th1
and Th2 cells were induced from B6 mice as follows (Fig. 1) (27). Either
unfractionated purified CD4 T cells or sorted CD62Lhigh CD44low naive CD4 T
cells from B6 mice spleen were cultured in tissue culture plates (precoated
overnight with 10 g/ml anti-CD3 monoclonal antibody [MAb] [clone 145-2C11;
BD Pharmingen] and 1 g/ml anti-CD28 MAb [37.51; BD Pharmingen]) in the
presence either of 5 ng/ml interleukin-12 (IL-12; PeproTech) with neutralizing 10
g/ml anti-IL-4 MAb (11B11; BD Pharmingen) for Th1 cells or of 5 ng/ml IL-4
(PeproTech) with neutralizing 10 g/ml anti-gamma interferon (IFN-) MAb
(37895; BD Pharmingen) for Th2 cells (Fig. 1). After 3 days, functional differ-
entiation of these cells was confirmed by observing the development of specific
cytokine production patterns by use of enzyme-linked immunosorbent assay
(ELISA) kits and intracellular cytokine staining (ICS) (27). Then, 1  107 Th1-
or Th2-skewed preparations of CD4 T cells were adoptively transferred into
B6.nude recipient mice, with fresh donor naive CD4 T cells from B6 mice serving
as the positive control.
(iii) Depletion of Thy1.2 CD4 T cells. Unfractionated, purified splenic CD4
T cells from normal B6 donor mice were stained with fluorescein isothiocyanate
(FITC) anti-Thy1.2 and phycoerythrin (PE) anti-CD4. Labeled CD4 T cells were
sorted by use of a FACStar Plus instrument with TurboSort to isolate the
Thy1.2 CD4 population. The purity of the resulting Thy1.2 CD4 population
was 99%. Either these cells or unfractionated CD4 T cells as a positive control
(1  107) were adoptively transferred into B6.nude recipients.
(iv) Isolation of CD45RBhigh/naive CD4 cells and CD45RBlow/memory CD4
cells from normal B6 splenocytes and adoptive transfer into B6.nude recipients.
First, splenic CD4 T cells from normal B6 donor mice were purified by using
Miltenyi beads as detailed above. After saving enough CD4 T cells for use as the
unfractionated polyclonal CD4 T-cell control, we labeled the rest of the CD4 T
cells with FITC anti-CD4 (H129.19) and PE anti-CD45RB (16A) (BD Pharmin-
gen). These labeled cells were sorted at high speed on a FACStar Plus instru-
ment with TurboSort. Based on our and another laboratory’s experience (28), the
CD45RBhigh and CD45RBlow populations were defined as the CD45RB bright-
est-staining 30% and dullest-staining 15%, respectively, of the CD4 cells. Purity
of CD45RBhigh CD4 and CD45RBlow CD4 populations was 98%. CD4 T cells
(0.5  107 to 1  107) (either CD45RBhigh, CD45RBlow, or unfractionated CD4
T cells as a positive control) were transferred into each B6.nude recipient.
(v) Depletion of CD45RBlow CD25 CD4 T-regulatory cells. Unfractionated,
purified, splenic CD4 T cells from normal B6 donor mice and CD4 T cells sorted
into CD45RBhigh and CD45RBlow subsets were obtained as described immedi-
ately above, except that the CD45RBlow CD4 T cells were separated into
CD45RBlow CD25 versus CD45RBlow CD25 cells by sorting cells labeled with
FITC anti-CD4 (H129.19), PE anti-CD45RB (16A) (BD Pharmingen), and allo-
phycocyanin (APC) anti-CD25 (7D4; eBioscience). Alternatively, B6 mice were
first injected i.p. with 250 g per mouse of anti-CD25 (hybridoma PC61) MAb
4 days prior to their use as donors for isolation of the CD45RBlow CD25 CD4
subset; the efficiency of depletion of the CD45RBlow CD25 CD4 cells was
90% as monitored by staining with anti-CD25 (7D4). Anti-CD25 (IL-2R)
MAb used in vivo was generated from hybridoma PC61 (29, 42) and purified via
elution over a protein G agarose column (Sigma). The antibody immunoglobulin
G (IgG) concentration was determined by comparison to commercial rat anti-
mouse CD25 MAb (PC61; eBioscience) in flow cytometric analyses employing
FITC-labeled goat anti-rat secondary antibody and indirect immunofluorescence
as a standard. Purified rat-IgG1 was used as a normal rat IgG control. Then,
spleen cells from these anti-CD25 MAb-treated donor mice were processed in a
fashion identical to that described above to yield CD45RBhigh, CD45RBlow, and
CD45RBlow CD25 CD4 T cells.
(vi) Depletion of CD25 CD4 T-regulatory cells. Unfractionated CD4 T cells
isolated from normal B6 splenocytes were stained with FITC anti-CD25 (7D4)
and PE anti-CD4 MAb (H129.19) (BD Pharmingen). Labeled CD4 T cells were
sorted by use of a FACStar Plus instrument with TurboSort to isolate the CD25
FIG. 1. Generation of CD4 Th1-like and Th2-like cells. CD62Lhigh
CD44low T cells were enriched by cell sorting (see Materials and
Methods) and cultured in 96-well plates of precoated anti-CD3 and
anti-CD28 with a 72-h stimulation. Stimulation was in the presence of
IL-12 and anti-IL-4 for Th1 cells and in that of IL-4 and anti-IFN- for
Th2 cells. Assays utilized for determining the functional differentiation
of Th1 and Th2 cells are indicated at the bottom.
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CD4 population. The purity of the resulting CD25 CD4 population was 99%.
Either these cells or unfractionated CD4 T cells as a positive control (1  107)
were adoptively transferred into B6.nude recipients. Alternatively, we first em-
ployed negative selection of CD4 T cells by using a biotinylated MAb cocktail to
deplete CD8, CD19, CD11b, and CD11c cells. For the resulting CD4 T-cell
population, this procedure was followed by Miltenyi bead positive deletion of
CD25 CD4 T-regulatory (Treg) cells. The purity of the entirely negatively
selected flowthrough CD25 CD4 T cell population was 99%.
ELISA determinations of serum Ig. For measuring hyper-Ig, affinity-purified
goat anti-mouse IgM and IgG2a antibody (Southern Biotechnology, Birming-
ham, AL) was diluted to 7 g/ml in phosphate-buffered saline (PBS) to coat
96-well ELISA-grade plates (Becton Dickinson, Oxford, CA) overnight at room
temperature. The plates were then washed three times with PBS and blocked for
1 h with 5% bovine serum albumin-PBS (Sigma, St. Louis, MO) at 37°C. Either
control uninfected sera or sera obtained at various time points after LP-BM5
infection and at the final termination time point were then plated and allowed to
incubate for 2 h at 37°C. The plates were washed three times with PBS, and
alkaline phosphatase-labeled goat anti-mouse Ig (Southern Biotechnology) was
added. After a 2-h 37°C incubation, p-nitrophenyl phosphate (Sigma) provided a
colorimetric change which was then quantitated at 405 nm by an ELISA reader
(Dynatech Laboratories, South Hampton, United Kingdom).
Spleen cell responses to mitogen. Spleen cells (4  105/well) from control and
experimental mice were plated in triplicate into 96-well plates with medium
containing 5% fetal calf serum, L-glutamine, antibiotics, and a final concentration
of 10 g/ml lipopolysaccharide (LPS). After 72 h, wells were pulsed with 1 Ci
of [3H]thymidine (Dupont NEN, Boston, Mass.) and harvested 6 h later onto
Unifilter 96-well GF/C plates for assessment of thymidine incorporation by
scintillation counting (Packard MicroSant NXT counter).
Flow cytometry. Spleen cells were incubated with FITC-, PE-, APC-, or Cy-
Chrome-conjugated antibodies, and the resulting direct immunofluorescence
was analyzed by use of a FACSCalibur flow cytometer (BD Bioscience) to detect
the expression of murine CD4 (H129.19), CD45RB (16A), CD25 (7D4 or PC61),
CD8a (53-6.7), Thyl.2 (53-2.1), B220 (RA3-6B2), CD19 (1D3), CD11b (M1/70),
CD11c (HL3), CD62L (MEL-14), CD44 (IM7), IFN- (XMG1.2), and IL-4
(11B11) (BD Pharmingen or eBioscience). Appropriate FITC-, PE-, APC-, or
Cy-Chrome-conjugated Ig isotypes of irrelevant specificity were used to control
for each experimental MAb. ICS of IFN- and IL-4 was performed as previously
described (27). Briefly, for ICS, cells were cultured with 50 ng/ml phorbol my-
ristate acetate (Sigma) and 1 g/ml ionomycin (Sigma) for 5 h, with 5 g/ml
brefeldin A added for the last 2 h. Extracellular staining with FITC anti-CD4 was
performed and followed by intracellular staining with PE anti-IFN- and APC
anti-IL-4. Stained cells were analyzed on a FACSCalibur flow cytometer using
Cellquest software (BD Bioscience).
RNA isolation and real-time quantitative RT-PCR. Viral load was determined
for BM5def and BM5eco as previously described (9, 16). Briefly, total RNA was
isolated from spleen tissue using Tri-Reagent (Molecular Research Center, Cin-
cinnati, OH) and treated with a DNA-free kit (Ambion, Austin, TX). Following
reverse transcriptase amplification of cDNA (Bio-Rad iScript cDNA synthesis
kit), quantitative reverse transcriptase PCR (RT-PCR) was performed using iQ
SYBR green supermix and iCycler software (Bio-Rad, Hercules, CA).
RESULTS AND DISCUSSION
Adoptive transfer of CD4 T cells converts MAIDS-resistant
B6.nude recipients to a MAIDS-susceptible phenotype. We
first compared positive and negative selection methods of
purifying mature splenic CD4 T cells from normal donor
C57BL/6 mice by experiments utilizing adoptive transfer of
CD4 T cells into B6.nude recipients. The mice were infected
with LP-BM5 virus i.p. 48 h after reconstitution, and progres-
sion to MAIDS was evaluated 9 to 11 weeks later. The follow-
ing standard readouts of MAIDS-associated symptoms, which
we and others have previously established, were employed
(16–20, 23, 37, 39): (i) spleen size, with enlargement indicating
MAIDS-associated B- and T-cell lymphoproliferation; (ii) se-
rum IgG2a and IgM levels, with increases due to MAIDS
polyclonal B-cell activation; and (iii) splenic B-cell responses
to LPS stimulation, with decreases indicative of B-cell-associ-
ated MAIDS-induced immunodeficiency. For all the experi-
ments, an early activational MAIDS disease parameter, hyper-
gammaglobulinemia (serum IgM and IgG2a levels), was also
assessed at about 7 to 8 weeks postinfection (p.i.) by analysis of
serum taken without sacrifice of the mouse. We routinely re-
peated the hyper-Ig determination and added cell-based
MAIDS parameters when we terminated the experiments.
In an initial experiment, purified mature splenic CD4 T cells
obtained by either positive or negative selection mediated
MAIDS by all standard readouts when they were adoptively
transferred into B6.nude recipients subsequently infected with
LP-BM5. There were no substantial differences in the patterns
of results obtained with the positive-selection and negative-
selection approaches, and the results were also comparable to
those observed for intact B6 mice. Here, for the sake of brevity,
we show only one activational parameter of MAIDS (spleen
weight) (Fig. 2A) and one immunosuppressive parameter (LPS
mitogen response) (Fig. 2B), although all disease readout as-
says were performed and showed the same pattern of results.
FIG. 2. Both positively and negatively selected CD4 T cells mediated LP-BM5-induced MAIDS when transferred into B6.nude recipients. CD4
T cells positively or negatively selected from B6 donors (1  107) were adoptively transferred into B6.nude recipients. Disease was assessed at 10
weeks p.i. by measuring splenomegaly (A) and immunodeficiency (B); the latter was measured by lymphocyte proliferation in response to LPS.
Results were compared to those from uninfected control mice and were significant (, P  0.05) or not significant (, P  0.05) by the Student
t test, with the Bonferroni adjustment applied as a multiple comparisons posttest. The data shown are representative of a total of three experiments,
with the same pattern of results always obtained.
VOL. 80, 2006 CD4 T CELLS IN THE PATHOGENESIS OF MURINE AIDS 5779
Considering that these were reproducible results in repeat
experiments, these data confirmed that positive selection of
CD4 T cells was a valid approach for use in additional adoptive
transfer experiments to define their required characteristics to
mediate LP-BM5-induced disease. Also of note is the fact that
viral loads for both the BM5def and BM5eco viral constituents
of LP-BM5 were determined at the termination of this kind of
experiment. Importantly, there was no reproducible difference
between the viral load for infected B6.nude mice that received
adoptive transfer of CD4 T cells and that for those mice that
did not receive such reconstitution for either the BM5def virus
or the BM5eco virus (data not shown). In addition, this viral
expression level was similar to that observed for infected wild-
type B6 mice (see Fig. 9 and the discussion of viral load below).
The relative contributions of Th1 and Th2 CD4 T-cell func-
tional subsets in MAIDS pathogenesis. A large body of evi-
dence has indicated the existence of functionally polarized
CD4 T-cell responses based on their profiles of cytokine se-
cretion, and CD4 T cells have thus been divided into the Th1
and Th2 subpopulations. It has generally been accepted that a
Th1/Th2 imbalance underlies various immune diseases. In
HIV-infected patients and LP-BM5-infected mice, T-cell pro-
liferation and Th1 cytokine (IL-2 and IFN-) production have
been reported to decline, while Th2 cytokine (IL-4, IL-5, IL-6,
and IL-10) and immunoglobulin production increase (4, 5, 10,
12, 26, 34, 45, 49, 57).
However, whether Th1 and/or Th2 cells and their associated
cytokines are critical for the induction of MAIDS pathogenesis
remains unknown. In this study, we directly tested the possible
requirement for Th1 versus Th2 CD4 T cells in vivo by cell
transfer with Th1 or Th2 cells induced and characterized in
vitro. We followed currently accepted standard protocols (Fig.
1; also see Materials and Methods) to skew either unfraction-
ated or purified CD62Lhigh CD44low naive CD4 T cells from B6
donors into Th1 and Th2 subpopulations in vitro, as deter-
mined by intracellular cytokine staining for IL-4 and IFN-
expression. In each case, the ratio of the percentages of CD4 T
cells expressing IFN- versus IL-4 was appropriately skewed
after differentiation into the Th1 (IFN-) and Th2 (IL-4) sub-
sets. However, higher background levels of IFN- by Th2 cells
or IL-4 for Th1 cells were observed when total CD4 T cells
were the starting source. In an attempt to decrease these back-
ground levels, previously activated or memory CD4 T cells
were removed from normal B6 splenocytes by sorting naive
CD62Lhigh CD44low CD4 T cells prior to Th1-versus-Th2
skewing in vitro.
FIG. 3. CD4 Th1 and Th2 cells equally mediate MAIDS. Naive CD62Lhigh CD44low CD4 T cells were purified from normal B6 splenocytes
before Th1 and Th2 skewing in vitro. The subsets were verified by IFN- (Th1) and IL-4 (Th2) production, as determined by intracellular cytokine
staining (A) and ELISA (B). CD62Lhigh CD44low Th1, Th2, or control nonskewed CD4 T cells (1  107) were adoptively transferred into B6.nude
recipients. At 9 weeks p.i., mice were assayed for disease by examination of hypergammaglobulinemia via ELISA measurement of serum Ig levels
(C) and of immunodeficiency via lymphocyte proliferation following LPS stimulation for 72 h (D). To depict the uninfected control, the data from
all groups of uninfected mice receiving the different transfers of experimental cell populations were pooled for simplicity because the values were
very similar. With both disease parameters, mice reconstituted with Th1, Th2, or control CD4 T cells showed significant disease (, P  0.05) by
the Student t test compared with uninfected mice. Furthermore, no significant difference (, P  0.05) was observed in the disease measurements
among the three infected groups that received cell transfers, with the Bonferroni adjustment applied as a multiple comparisons posttest. The data
shown are representative of three total experiments, with the same pattern of results always obtained.
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By this approach, highly polarized IFN--producing Th1 or
IL-4-producing Th2 responses were generated as assayed by
both intracellular cytoplasmic staining and flow cytometry (Fig.
3A) and IL-4 and IFN- protein secretion as determined by
ELISA (Fig. 3B). Th1 and Th2 CD4 T cells were adoptively
transferred into B6.nude recipients, which were then subjected
to LP-BM5 infection. Progression to full MAIDS was evalu-
ated by sacrificing the mice and assessing the standard read-
outs for MAIDS. However, the MAIDS disease activational
parameter hyper-IgM and -IgG2a levels were periodically as-
sessed at interim time points postinfection by analysis of serum
samples, and the same pattern of results indicating clear in-
duction of disease was obtained. That is, both CD4 Th1 and
Th2 cells were clearly able to mediate MAIDS after infection
with LP-BM5. Substantial disease was evident by both activa-
tional parameters (spleen weight [P  0.05] [data not shown]
and hyper-IgM and -IgG2a [P  0.05] [Fig. 3C]) and an im-
munosuppressive parameter (LPS response [P  0.05]) (all
compared with uninfected control groups [Fig. 3D]). Con-
versely, when comparing the extents of MAIDS mediated by
donor Th1 versus Th2 versus unfractionated CD4 T cells,
the B6.nude recipients displayed roughly the same degree of
MAIDS (P  0.05) by spleen weight (data not shown),
hyper-IgM and -IgG2a levels (Fig. 3C), and LPS responsive-
ness (Fig. 3D).
Are Thy1.2 CD4 cells central to MAIDS pathogenesis? A
CD4 T-cell subset that uniquely expands upon LP-BM5-in-
duced MAIDS pathogenesis was next examined to determine if
it plays a causal role in this disease. Of the CD4 T cells derived
from the B6 mice that are utilized here as the prototypic
MAIDS-susceptible strain, all are also Thy1.2, except for
about 1% which are Thy1.2. A report from the laboratory of
Morse and coworkers (24) demonstrated, however, that this
small Thy1.2 CD4 T-cell subpopulation increased substan-
tially following LP-BM5 infection. We have previously con-
firmed this finding (16), e.g., the ratio of Thy1. 2 CD4 among
total CD4 T cells increased from 5% (Fig. 4A, left) to 42%
(Fig. 4A, right) after LP-BM5 infection. To test for a possible
functional role for this rare CD4 T-cell subset in MAIDS
induction, we purified Thy1.2 CD4 T cells (Fig. 4A, bottom)
and thereby deleted Thy1.2 CD4 T cells from B6 donors (Fig.
4A, left). After adoptive transfer of only the purified Thy1.2
CD4 T cells into B6.nude recipients and subsequent LP-BM5
infection, we assessed MAIDS pathogenesis by spleen weight
(Fig. 4B) and all the other standard MAIDS readouts (data not
shown). It was clear that there was no significant difference
between the B6.nude recipients reconstituted with total CD4 T
cells and those reconstituted with Thy1.2 CD4 T cells only.
Furthermore, at the termination of the experiment, flow cyto-
metric analysis indicated that there was no LP-BM5 infection-
dependent increase of Thy1.2 CD4 T cells from the very small
percentages of such contaminating cells in B6.nude mice re-
ceiving purified Thy1.2 CD4 T cells. This lack of increase
(i.e., 0.9-fold) of the average percentage of Thy1.2 CD4 T
cells (of total CD4 T cells) is to be contrasted with the 3.7-fold
increase in the Thy1.2 T-cell level for the infected Bb.nude
group reconstituted with total CD4 T cells over that for the
noninfected but similarly reconstituted group. Thus, because
purified Thy1.2 CD4 T-cell transfer leads to an equivalent
level of disease (Fig. 4B), there was no evidence that Thy1.2
CD4 T cells played a key role in MAIDS pathogenesis. In
addition, it is not clear whether the increase in the Thy1.2
CD4 T-cell subpopulation is a result of an actual expansion of
these cells or whether it (also) involves Thy1.2 downregulated
expression on previously Thy1.2 cells.
Do the required CD4 T cells need to be of the CD45RBhigh/
naive or the CD45RBlow/memory phenotype to mediate LP-
BM5 induction of MAIDS? In this series of experiments, the
goal was to focus on whether previous antigen experience
acquired through the T-cell receptor governs the pathogenic
ability of CD4 T cells in MAIDS. To this end, we separated
CD45RBhigh/naive CD4 cells and CD45RBlow/memory CD4
cells from normal B6 mice splenocytes and adoptively trans-
ferred such purified subsets into B6.nude recipients. MAIDS
disease parameters were again assessed both at about 7 to 8
FIG. 4. Thy1.2 CD4 T cells are not necessary for the induction of MAIDS pathogenesis. Phenotyping of spleen cells following LP-BM5
infection of B6 mice showed an increase of Thy1.2 CD4 T cells from 1% (A, upper left) to about 12.5% at 9 weeks p.i (A, upper right). Thy1.2
CD4 T cells were depleted from normal, uninfected B6 donors (A, upper left), and 1  107 purified Thy1.2 CD4 T cells (purity, 99.8%) (A,
bottom) were adoptively transferred into B6.nude recipients. At 9 weeks p.i., mice were assayed for disease activation by assessment of
splenomegaly (B). These results were highly consistent with the data obtained for other disease parameters (data not shown), and showed that,
similar to infected wild-type intact B6 mice, recipients reconstituted with either Thy1.2 or total CD4 T cells developed similar levels of MAIDS
(, P  0.05). The data shown are representative of two total experiments, with the same pattern of results always obtained.
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weeks p.i. by analysis of serum and at the 9- to 11-week ter-
minal time point by use of spleen cell readouts.
Positively selected total CD4 T cells (Fig. 5A, left) from
normal B6 splenocytes were subsequently stained with
CD45RB-PE. The CD45RBhigh and CD45RBlow populations
were empirically defined as the brightest-staining 30% and
dullest-staining 15%, respectively, of the CD4 cells (see Mate-
rials and Methods). The purities of the postsorted and pre-
transferred CD4 T-cell populations used were both 98%.
Equal numbers (0.5  107 to 1  107 in different experiments)
of CD4 T cells that were either CD45RBhigh (Fig. 5A, upper
right), CD45RBlow (Fig. 5A, lower right), or total unfraction-
ated (Fig. 5A, left) (as a positive control) were adoptively
transferred into B6.nude recipients, which were subsequently
infected with LP-BM5 virus. Reconstitution appeared to be
roughly equivalent; the adoptively transferred cells were as-
sessed at the termination time point of each experiment, and
approximately similar levels of recovery of CD4 T-cell numbers
were observed for B6.nude recipients that were reconstituted
with either CD45RBhigh or CD45RBlow cells. Although all
disease readouts were performed, here again only representa-
tive activation (Fig. 5B) and immunosuppressive (Fig. 5C) pa-
rameters are shown, since all disease readout assays were in
agreement.
Compared to uninfected mice that received control CD4 T
cells, both CD45RBlow and CD45RBhigh CD4 T cells clearly
mediated LP-BM5-induced MAIDS. Interestingly, however,
the extent of disease consistently seemed to depend on the
CD45RB status of the transferred CD4 T cells. For example,
the hyper-IgM and -IgG2a levels of the B6.nude recipients
reconstituted with the CD45RBlow CD4 cell group were sig-
nificantly lower than those of the B6.nude recipients reconsti-
tuted either with total CD4 or with CD45RBhigh CD4 T cells
(Fig. 5B). Similarly, the CD45RBlow CD4 T-cell-mediated re-
FIG. 5. CD4 CD45RBlow cells mediate MAIDS, but to a lesser degree than CD45RBhigh CD4 T cells. Purified CD4 T cells (A, left) from B6
donors were sorted into 30% brightest CD45RBhigh (A, upper right) and 15% dullest CD45RBlow (A, lower right) CD4 T cells. Equal numbers
(5  106) of CD45RBhigh, CD45RBlow, or total unfractionated (as a positive control) CD4 T cells were adoptively transferred into B6.nude
recipients. Disease parameters were determined at 9 weeks p.i. by assessment of hypergammaglobulinemia via ELISA measurement of serum IgM
and IgG2a (B) and of immunodeficiency via lymphocyte proliferation in response to LPS (C). Both CD45RBhigh and CD45RBlow CD4 T cells
mediated MAIDS compared with the uninfected control (, P  0.05); however, compared to B6.nude mice receiving CD45RBhigh or unfrac-
tionated CD4 T cells, recipients reconstituted with CD45RBlow cells mediated significantly less disease by the Student t test (, P  0.05), with
the Bonferroni adjustment applied as a multiple comparisons posttest. These results were consistent with all other disease parameters (data not
shown). The data shown are representative of two experiments, with the same pattern of results always obtained.
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sidual mitogenic response to LPS of the B6.nude recipients
reconstituted with CD45RBlow CD4 cells was significantly
higher than that of the B6.nude recipients reconstituted with
either total CD4 or CD45RBhigh CD4 T cells (Fig. 5C). In
contrast, donor CD45RBhigh cells mediated the immunodefi-
ciency of MAIDS after LP-BM5 infection to an extent similar
to that seen following transfer of unfractionated CD4 T cells.
Thus, CD45RBlow CD4 cells supported MAIDS but not to the
same degree as CD45RBhigh CD4 cells; this effect was ob-
served in the two experiments in which only these subsets
were compared and also in the subsequent more complex
experiments, in which the CD45RBlow subset was further
fractionated.
Do CD45RBlow CD25 CD4 T-regulatory cells inhibit
MAIDS development? One interpretation of the results given
above is that CD45RBlow CD4 T cells intrinsically support
significantly less MAIDS development than CD45RBhigh CD4
T cells. An alternative reason that the CD45RBhigh versus
CD45RBlow CD4 T-cell subsets might differentially support
LP-BM5-induced MAIDS is that the latter memory CD4 T-cell
population uniquely contains the natural Treg (nTreg) subset.
Perhaps these nTreg cells limit the extent of LP-BM5-induced
disease, either (i) as anergic cells by “diluting” the CD45RBlow
CD4 T-cell population and thus decreasing the percentage of
non-nTreg CD25 CD4 cells that are able to mediate MAIDS
pathogenesis present or (ii) by actively inhibiting or suppress-
ing the ability of the CD25 CD4 T cells to undergo activation
and proliferation upon LP-BM5 infection and thus to promote
viral pathogenesis.
Indeed, our experiments showed that in normal naive, un-
infected B6 mice, about 8.9% of the total CD4 population
consisted of CD25 nTreg cells (Fig. 6A, left). In contrast to
the starting distribution of Tregs, among the postsorted
CD45RBhigh CD4 T cells (Fig. 6A, middle), only 2.6% of cells
were CD25, whereas there were 16.7% CD25 Treg cells
among postsorted CD45RBlow CD4 T cells (Fig. 6A, right).
To address the possible negative role of nTreg cells in LP-
BM5-induced viral pathogenesis, we depleted CD25 CD4 T
cells from the CD45RBlow population. In addition to the un-
fractionated CD4 T cells and the CD45RBhigh and CD45RBlow
subsets purified as described above, a CD45RBlow population
depleted of CD25 CD4 T cells was adoptively transferred in
parallel into B6.nude recipients. In the representative experi-
ment shown in Fig. 6, we first confirmed, as for the experiment
shown in Fig. 5, the result that the extent of disease consis-
tently depended on the CD45RB status of transferred CD4 T
cells. In addition, there was no evidence that the CD45RBlow
CD25 nTreg population was able to moderate the ability of
CD45RBlow CD4 T cells to mediate MAIDS. The spleen
weight (Fig. 6B), hyper-IgM level (Fig. 6C), and mitogenic
FIG. 6. CD45RBlow CD25 CD4 natural T-regulatory cells do not inhibit MAIDS development. CD25 CD4 T cells (A) were quantified in a
total CD4 population (left) and in purified CD45RBhigh (middle) and CD45RBlow (right) populations. B6.nude recipient mice received 5  106
CD45RBhigh, CD45RBlow, CD45RBlowCD25, or CD45RBlowCD25 T cells or total CD4 T cells as a control via adoptive transfer. Following 10
weeks of LP-BM5 infection, mice were assayed for disease activation by assessments of splenomegaly (B); of hypergammaglobulinemia, as
determined by ELISA measurement of serum Ig levels (C); and of immunodeficiency, as determined by LPS-induced proliferation (D). Disease
activation levels were equivalent among B6.nude recipients reconstituted with total CD45RBlow, CD45RBlowCD25, or CD45RBlowCD25 CD4
T cells (, P  0.05) but significantly decreased (, P  0.05) when any of these three CD45RBlow subsets were transferred into B6.nude mice
compared to those reconstituted with CD45RBhigh or total CD4 T cells, with the Bonferroni adjustment applied as a multiple comparisons posttest.
VOL. 80, 2006 CD4 T CELLS IN THE PATHOGENESIS OF MURINE AIDS 5783
response to LPS (Fig. 6D) results showed that the CD45RBlow,
CD45RBlow CD25, and CD45RBlow CD25 reconstituted
groups were similar to each other. Further, these groups all
mediated significantly less MAIDS development than either
the unfractionated CD4 group or the CD45RBhigh group.
To further limit any contamination of nTreg cells in the
CD25-depleted CD45RBlow preparation, we treated donor
B6 mice with anti-CD25 MAb in vivo 4 days prior to purifica-
tion of CD45RBhigh, versus CD45RBlow, CD4 T cells and sub-
sequent further separation. After again obtaining a highly en-
riched (98% pure) CD25 CD4 cell population, we repeated
the adoptive transfer of unfractionated CD4, CD45RBhigh,
CD45RBlow, or CD45RBlow CD25 cells into B6.nude recipi-
ents. One of the representative activational disease parame-
ters, spleen weight (Fig. 7A), and one immunodeficiency pa-
rameter, mitogenic response to LPS (Fig. 7B), are depicted,
although these and all other disease readouts showed a pattern
of results identical to that shown in Fig. 6 when the B6 donor
mice were employed without in vivo anti-CD25 treatment prior
to the CD45RB purification. Thus, depletion of CD25 nTreg
cells from the CD45RBlow CD4 subset did not improve the
ability of the cells in this subset to mediate LP-BM5-induced
MAIDS.
Possible requirement for nTreg cells in MAIDS. Because
there was no evidence for the involvement of CD45RBlow
CD25 nTregs in modulating the extent of MAIDS patho-
genesis, while some CD4 CD25 potential nTregs are
CD45RBhigh (Fig. 6A) (13), it was important to determine
whether this nTreg subpopulation regulates viral pathogenesis
in the context of the naive, unmanipulated CD4 T-cell popu-
lation. Thus, CD4 T cells isolated from normal B6 splenocytes
(Fig. 8A, left) were stained with FITC anti-CD25 and PE
anti-CD4 and sorted such that CD25 CD4 T cells were col-
lected, free of CD25 nTreg CD4 T cells. The purity of CD25
CD4 T cells was 99% (Fig. 8A, right). These CD25-de-
pleted CD4 T cells, with unfractionated total CD4 T cells used
as a positive control, were adoptively transferred into B6.nude
recipients, and disease susceptibility was assessed as usual at 9
to 11 weeks p.i.
Measurements by all the MAIDS readouts provided the
same result: adoptive transfer of either total CD4 T cells or
CD25 CD4 T cells into B6.nude mice led to essentially iden-
tical amounts of disease. As examples of the MAIDS readouts,
one activational parameter, spleen weight (Fig. 8B), and one
immunosuppressive parameter, LPS response (Fig. 8C), are
depicted as representative findings.
To confirm these results and to further decrease the possi-
bility that a minor fraction of persisting CD25 nTregs was
present and sufficient to limit the extent of disease, we em-
ployed an alternative approach to perhaps more completely
eliminate the CD25 CD4 Treg cells. Thus, rather than per-
forming flow cytometric sorting, we depleted the CD4 CD25
nTreg cells by use of Miltenyi anti-CD25 beads. Again, how-
ever, there was no difference in the abilities of the CD25-
depleted CD4 T cells and the unfractionated CD4 T cells to
mediate MAIDS (data not shown). Thus, using several ap-
proaches collectively, we found no evidence that CD25
CD4 nTreg cells played an important role in MAIDS patho-
genesis, including that in the context of the total CD4 T-cell
population.
A decrease in disease pathogenesis mediated by CD45RBlow
CD4 T cells does not correlate with a reduction in viral load.
To determine if the observed decrease in the extent of LP-
BM5-induced MAIDS pathogenesis mediated by CD45RBlow
CD4 T cells might be due to a reduced viral load, the expres-
sion levels of the pathogenic BM5def and helper BM5eco
viruses were determined by quantitative RT-PCR assay (9, 16)
for the experiments shown in Fig. 5 through 7 with the repre-
sentative data from Fig. 6 as shown here. By this assay, the
levels of the BM5def and BM5eco viruses were not detectable
in uninfected mice, as expected (Fig. 9). Infected B6.nude
recipients that received previous transfer of total CD4 T cells
expressed high defective and ecotropic viral load levels, which
were approximately the same as those of the infected B6
group. B6.nude mice receiving adoptive transfer of either
CD45RBlow, CD45RBlow CD25, or CD45RBlow CD25 CD4
T cells, all of which mediated an extent of MAIDS pathogen-
esis lesser than that of the CD45RBhigh CD4 subset (Fig. 6 and
7), expressed approximately identical BM5def and BM5eco
viral load levels at 10 weeks after LP-BM5 infection. Impor-
FIG. 7. Further evidence that the decreased MAIDS pathogenesis mediated by CD45RBlow CD4 T cells cannot be attributed to inhibition by
CD25 nTreg cells. B6 donor mice were treated with anti-CD25 MAb in vivo 4 days prior to purification of CD45RBhigh, CD45RBlow, or total CD4
T cells. CD45RBhigh, CD45RBlow, CD45RBlow CD25, or control unfractionated CD4 T cells (6  106) were adoptively transferred into B6.nude
recipients. At 9 weeks p.i., disease was determined by assessments of splenomegaly (A) and of immunodeficiency by lymphocyte proliferation in
response to LPS stimulation (B). Results were significant (, P  0.05) or not significant (, P  0.05) by the Student t test, with the Bonferroni
adjustment applied as a multiple comparisons posttest.
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tantly and surprisingly, B6.nude recipients that received
CD45RBhigh CD4 T cells, which mediated substantially more
MAIDS pathogenesis (Fig. 6), expressed, if anything, some-
what lower BM5def and BM5eco viral levels in this experi-
ment, although this trend was not statistically significant (Fig.
9). In the other experiments (Fig. 5 and 7), the levels of
BM5def and BM5eco mRNA expression were even more sim-
ilar between the mouse groups receiving CD45RBlow cells
and/or CD45RBlow subsets and those receiving CD45RBhigh
CD4 T cells. Thus, clearly the reduced ability of CD45RBlow
CD4 cells to mediate LP-BM5-induced MAIDS could not be
ascribed to a reduced ability of LP-BM5 to infect, or of the
component viruses to be expressed in, B6.nude mice that re-
ceived these calls by adoptive transfer.
Implications of the present study. In the present study, we
sought to define the critical cell surface phenotypic and/or
functional characteristics of CD4 T cells, whose expression
allowed these T cells to mediate MAIDS pathogenesis upon
infection of susceptible B6 mice with the LP-BM5 retroviral
isolate. Thus, beyond the crucial ability to upregulate CD154
(CD40L) expression by these pathogenic CD4 T cells such that
CD40 B cells are activated and transmit the CD40-TRAF-6-
dependent signals necessary for disease induction (16–20), the
function of CD4 T cells in mediating MAIDS is incompletely
FIG. 8. Lack of evidence that CD4 CD25 nTreg cells substantially modulate MAIDS disease as mediated by an intact CD4 T-cell population.
CD25 T cells (A, left) were gated and then sorted from total CD4 T cells, leaving a highly purified (99%) CD25 CD4 T-cell population (A,
right). CD4 CD25 or total CD4 cells (1  107) were adoptively transferred into B6.nude recipients. Mice were assayed for disease activation at
9 weeks p.i. by assessments of splenomegaly (B) and of immunodeficiency by examining lymphocyte proliferation in response to LPS stimulation
(C) (, P  0.05; , P  0.05). The Bonferroni adjustment was applied as a multiple comparisons posttest. This experiment was repeated, with
the slight modification that the CD25 CD4 nTreg cells were removed by Miltenyi beads instead of by flow cytometric sorting. However, the same
pattern of results was obtained.
FIG. 9. Decreased viral pathogenesis mediated by CD45RBlow
CD4 T cells does not correlate with reduced viral load. In this real-time
RT-PCR assay, expressions of the BM5def (DEF) and BM5eco (ECO)
viruses were normalized to the expression of 	-actin. The data de-
picted represent the means and standard deviations of two indepen-
dent replicate assessments of each sample (each assessment based on
duplicate determinations). Results were significant (, P  0.05) or
not significant (, P  0.05) by the Student t test, with the Bonferroni
adjustment applied as a multiple comparisons posttest. Shown here are
the results for viral load for the mouse groups shown in Fig. 6 as
representative data for BM5def and BM5eco virus expression also
determined for the experiments shown in Fig. 5 and 7 (see Results and
Discussion).
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understood. Included in the unresolved issues is the question
of whether the functional/phenotypic parameters that have
been observed for CD4 T cells obtained from mice with ongo-
ing MAIDS—such as differential cytokine production, anergic
characteristics, and altered cell surface properties—are rele-
vant to their required functional role in the induction of
MAIDS pathogenesis. Alternatively, these changes simply may
be markers of the effects of established disease on the CD4
T-cell compartment.
To separate the requirements for MAIDS induction that
operate at the level of the necessary CD4 T-cell population
from possible MAIDS epiphenomena, we utilized an adoptive
transfer approach to directly compare the abilities of different
CD4 T-cell subsets to reconstitute B6.nude mice for suscepti-
bility to LP-BM5-induced MAIDS. By use of this approach,
some of the characteristics of CD4 T cells from LP-BM5-
infected mice with disease, e.g., the lack of expression of the
Thy1 (CD90) marker by the MAIDS-expanded unique popu-
lation of CD4 Thy1 (CD3) T cells (Fig. 4), were found to
likely be irrelevant to CD4 T-cell pathogenic function. Thus,
there was no effect of the removal of Thy1 CD4 T cells;
rather, this depleted CD4 T-cell population mediated full-
blown MAIDS upon LP-BM5 infection.
Similarly, we found no consistent difference in the abilities of
CD4 T-cell populations that were skewed to the Th1 versus
Th2 functional subsets to mediate LP-BM5-induced MAIDS in
the adoptive transfer model (Fig. 1 and 3). Consideration of a
possible differential role of Th1 versus Th2 cells as the re-
quired pathogenic CD4 T cells was pertinent, given the existing
literature on both cytokine production specifically in MAIDS
(11, 35, 36, 38) and the critical function of Th1/Th2 CD4 T cells
in various other disease states. Thus, in addition to playing
differential roles in protection, polarized Th1-type and Th2-
type responses are also responsible for different types of im-
munopathological reactions. Th1 cells are involved in the
pathogenesis of several organ-specific autoimmune disorders.
In contrast, allergen-specific Th2 responses may be critical for
atopic disorders in genetically susceptible individuals, and
skewing to a Th2 response in certain infections diseases, such
as leishmaniasis, leprosy, and others, results in a lack of clear-
ance of the causative microbe and consequently in enhanced
microbial and/or immunological pathology (4, 34, 45, 57).
More germane to the present murine retroviral immunode-
ficiency system is the fact that, for HIV type 1 infection, the
potential role of cytokines in the development of AIDS has
received a great deal of attention. There is some evidence
suggesting that a Th2-type cytokine response is often associ-
ated with progression to AIDS in HIV-positive individuals (4,
5, 10, 12, 34, 49, 57). Thus, it seemed important to study here
the question of whether the Th1 and Th2 subsets were differ-
entially able to mediate LP-BM5-induced MAIDS pathogen-
esis. However, we could find no evidence to support this pos-
sibility. In experiments utilizing adoptive transfer of Th1 or
Th2 CD4 T-cell functional subsets, with appropriate differen-
tial IFN- versus IL-4 cytokine profiles confirmed as skewed in
vitro (Fig. 3A and B), into B6.nude recipients, both subsets
mediated MAIDS induction equally (Fig. 3C and D). This
result, obtained by direct comparison of Th1 T cells to Th2
CD4 T cells, was important given the conflicting results ob-
tained in the past on Th1 versus Th2 involvement in MAIDS.
In particular, many previous studies attempted to imply a dis-
ease-causing role for Th2 CD4 T cells simply by correlating
Th2 cytokine production during ongoing MAIDS. Our result is
in keeping with two other studies that also utilized more-direct
approaches to examine the need for Th2 T cells in MAIDS:
these studies found (i) that when mice with a genetic disrup-
tion of the IL-4 gene, but specifically fully backcrossed onto the
susceptible B6 background, are used, MAIDS develops nor-
mally following LP-BM5 infection (35, 36), and (ii) that B6
mice deficient in STAT6, which is the proximal signal trans-
ducer of ligated IL-4 receptor, also exhibited normal suscep-
tibility to the induction of MAIDS (38).
For some of the other functional/phenotypic parameters of
CD4 T cells, the results and their implications were more
complicated and deserve a more detailed consideration. These
issues include the level of expression of CD45RB by the patho-
genic CD4 T cells and the possible involvement of CD25 CD4
nTregs. Our results from comparison of CD45RBhigh naive/
non-antigen-experienced to CD45RBlow memory/antigen-ex-
perienced CD4 T cells indicated that while both functional
subsets supported MAIDS induction and progression, only the
CD45RBhigh subpopulation mediated full disease after LP-
BM5 infection (Fig. 5B and C). In contrast, the CD45RBlow
memory subset consistently (Fig. 5, 6, and 7) supported only
40% to 55% as much pathogenesis, and this was consistent
across all MAIDS disease parameters. This decreased severity
of MAIDS was not due to a reduced ability of the B6.nude
mice receiving a CD45RBlow CD4 T-cell transfer to become
infected by, or to express, the LP-BM5 retrovirus. Thus, quan-
titative real-time PCR analysis clearly indicated that both the
pathogenic BM5def and the helper BM5eco component vi-
ruses were expressed at least as well in the CD45RBlow recip-
ient mice (Fig. 9). Therefore, either or both of the following
two explanations seemed most likely. (i) CD45RBlow CD4 T
cells have intrinsic properties on a per-cell basis that prohibit
them from being able to fully support MAIDS induction,
and/or (ii) the CD25 CD4 natural Treg population largely
contained within the CD45RBlow compartment inhibits the
ability of the pathogenic effector CD4 T cells also in this
compartment to mediate LP-BM5-induced MAIDS.
The possibility that nTreg cells were involved was tested
first, particularly as their relatively recent identification has led
to an explosion of literature reports demonstrating their criti-
cal involvement in the regulation of T-cell responses, including
in a variety of disease states (43, 50, 51, 53). In short, a sub-
population of normal CD4 T cells that coexpresses the inter-
leukin-2 receptor (IL-2R)  chain (CD25) has been defined as
a suppressive nTreg population that appears to play an impor-
tant function in controlling the development of autoimmune
diseases and other immune responses, including Th1/inflam-
matory-type phenomena (43, 51, 53). The naturally occurring
murine CD45RBlow CD25 CD4 nTreg cells have been shown
to prevent T-cell-mediated immune pathology in several dis-
ease models, especially autoimmune processes, and there is
now evidence that CD25 CD4 nTregs may be involved in
many other aspects of immunoregulation, including the re-
sponses to autoantigens, alloantigens, tumor antigens, and
pathogen-derived antigens and even the maintenance of nor-
mal pregnancy (14, 31, 32, 40, 44, 48, 50, 51, 54).
Although other cell surface markers have been associated
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with various Treg cell populations, including GITR (glucocor-
ticoid-induced tumor necrosis factor receptor) and CTLA-4
(30, 53, 56), none is truly specific for Treg cells, as these
markers can also be expressed by activated CD4 CD25
T-effector cells (51). CD25 has been and continues to be the
most prominent and defining marker for specifically nTreg
cells. As a cell surface marker, CD25 is very useful for obtain-
ing cell preparations that are highly enriched for, or depleted
of, Treg cells in order to analyze their function. Thus, although
FoxP3 has recently emerged as the best marker of functional
Treg cells, it is a transcription factor whose identification by
cytoplasmic staining does not lend itself to purification of via-
ble cells for functional testing (53).
In the present study, we addressed the possible regulatory
role of nTreg cells in MAIDS by use of an adoptive transfer
system featuring B6.nude recipient mice. Naive mouse donor
sources of pathogenic CD4 T cells, either (i) the CD45RBlow
subset that mediates partial LP-BM5 retrovirus-induced
MAIDS pathogenesis relative to the CD45RBhigh subset or (ii)
the unfractionated total CD4 population, were efficiently de-
pleted of CD25 CD4 nTreg cells by several approaches (Fig.
6 through 8). This effectiveness of nTreg depletion coupled
with the use of B6.nude recipients provided an appropriate
system by which nTreg cells were removed during the entire
course of the LP-BM5 infection. Thus, it has been recently
confirmed that nTreg development requires selection in an
intact thymus (30, 53, 56) and reported that CD11c major
histocompatibility complex class II thymic medullary den-
dritic cells that are activated by thymic stromal lymphopoietin
to express high levels of CD80 and CD86 are required for the
induction of the proliferation and differentiation of thymocytes
into CD25 FoxP3 CD4 nTreg cells (58).
However, despite the use of the B6.nude adoptive transfer
system to eliminate nTreg cells, MAIDS developed upon LP-
BM5 infection. CD45RBlow CD4 T cells continued to mediate
MAIDS pathogenesis at reduced levels whether or not CD25
CD4 nTregs were present (Fig. 6 and 7), indicating that their
decreased pathogenic function was not due to CD45RBlow
nTreg suppression. Full-blown MAIDS was also observed de-
spite the depletion of nTregs from the unfractionated naive
CD4 population (Fig. 8). Therefore, there was no evidence for
the involvement of nTregs in the intact CD4 system. In addi-
tion, based on the nearly complete inhibition obtained by
blocking anti-CD80/CD86 MAb treatment, it has been re-
ported that nTreg differentiation in the thymus requires CD80/
CD86 expression (58). Therefore, our results here favoring a
lack of nTreg involvement in MAIDS are supported by our
earlier study showing that B6.CD80/CD86 double-knockout
mice are MAIDS susceptible (17).
We thus have evidence arguing against the involvement of
CD25 nTregs and any other Tregs that derive from a CD25
precursor cell. However, we cannot exclude the possible role of
other CD4 Treg populations in LP-BM5-induced MAIDS ini-
tiation or progression. In addition to CD25 nTregs and their
progeny, there are at least two other distinct CD4 Treg subsets:
(i) type 1 T-regulatory cells (Tr1), or “inducible” Tregs (33, 46,
47), and (ii) Th3-type Tregs (1, 30, 43). It is possible that either
or both of these Treg cell types may derive from CD25 CD4
T cells. In particular, given that MAIDS induction stems from
retroviral infection, the inducible Tr1 regulatory cells are an
attractive candidate. Along these lines, a study by Beilharz et
al. (6) reported that MAIDS pathogenesis is partially reduced
by in vivo antibody treatment. The antibody injections were
given every fourth day beginning at 2 days preinfection and
continued to 18 days postinfection. Certain combinations of
two or three antibodies injected simultaneously led to a de-
crease in LP-BM5-induced splenomegaly. In contrast, other
combinations, i.e., of a group consisting of MAbs against
CD25, CTLA-4, and GITR, or these MAbs used singly, had no
significant effect. However, this approach could not distinguish
between a blocking effect of these antibodies on Treg cells, as
was suggested, versus effects on pathogenic CD4 T effector
cells. This is of concern, especially since GITR is known to be
a costimulatory receptor for CD4 effector cells in other systems
(30, 53). Thus, the possibility of Tr1 Treg involvement in
MAIDS demands further consideration. Such future studies
will require new reagents and/or approaches that will allow for
the separate manipulation of the Treg and pathogenic effector
CD4 T-cell compartments.
In summary, our results argue against a role for nTreg cells
in MAIDS pathogenesis. Rather, an intrinsic defect in the
CD45RBlow CD4 T-cell population is implied as the underly-
ing reason for its reduced MAIDS pathogenic potential in
conjunction with LP-BM5 infection. Determining whether it is
the antigen-experienced/memory phenotype that is character-
istic of this subset per se or other associated phenotypic or
functional parameters that form the basis for this difference
will require additional experimentation. However, the present
results provide further insight into the involvement of CD4
T-cell subsets in this retrovirus-induced disease model and
highlight the heterogeneity of this cellular compartment, which
is required for MAIDS pathogenesis.
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